

UK Trial of Radioiodine Intervention in Subclinical Hyperthyroidism

Submission date 16/12/2005	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/08/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 13/11/2017	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Simon Pearce

Contact details
School of Clinical Medical Sciences
University of Newcastle
Newcastle upon Tyne
United Kingdom
NE2 4HH
-
s.h.s.pearce@ncl.ac.uk

Additional identifiers

Protocol serial number
G0500783

Study information

Scientific Title
UK Trial of Radioiodine Intervention in Subclinical Hyperthyroidism

Acronym

TRISH

Study objectives

Radioiodine treatment for sustained subclinical hyperthyroidism will not reduce circulatory endpoints in the elderly.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval gained from the Newcastle and North Tyneside Research Ethics Committee (reference number: 06/Q0905/112).

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Subclinical hyperthyroidism

Interventions

Radioiodine treatment versus usual care.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Radioiodine

Primary outcome(s)

Composite circulatory mortality

Key secondary outcome(s))

1. All cause mortality
2. Atrial fibrillation
3. Progression to overt hyperthyroidism
4. Hip and vertebral fractures
5. MMTS

Completion date

30/09/2015

Eligibility

Key inclusion criteria

1. Over 65 years of age
2. Sustained subclinical hyperthyroidism (undetectable Thyroid Stimulating Hormone [TSH], normal free thyroid hormones) for greater than three months

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

1. Patient currently has or has ever had Atrial Fibrillation (AF)
2. Certain drug usage
3. Pituitary, severe renal or hepatic disease
4. Unstable coronary disease

Date of first enrolment

01/10/2006

Date of final enrolment

30/09/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

School of Clinical Medical Sciences

Newcastle upon Tyne

United Kingdom

NE2 4HH

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Trust (UK)

ROR

<https://ror.org/05p40t847>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008		Yes	No